Claims

[Claim 1]
Use of a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X in the manufacture of a medicament for treating and/or reducing the incidence of a disease that develops and/or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII (FVIII) and/or activated blood coagulation factor VIII (FVIIIa),

wherein the bispecific antibody is to be administered to a subject at a weekly loading dose of 3 mg/kg of the antibody for four weeks; and, after the loading dose administrations are complete, a maintenance dose of the antibody is to be administered to the subject one or more times, wherein the maintenance dose is 6 mg/kg of the antibody and it is to be administered to the subject every four weeks in a single dose or multiple divided doses,

wherein the disease is hemophilia A, acquired hemophilia A, von Willebrand disease, or hemophilia A with emergence of an inhibitor against FVIII and/or FVIIIa and

wherein the bispecific antibody is:

(a) a bispecific antibody comprising a first polypeptide which is an H chain containing an H chain variable region containing CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively; a second polypeptide which is an H chain containing an H chain variable region containing CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively; and a third and fourth polypeptide which are a commonly shared L chain containing an L chain variable region containing CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 11, 12, and 13, respectively;

(b) a bispecific antibody comprising a first polypeptide which is an H chain containing an H chain variable region amino acid sequence of SEQ ID NO: 4;
a second polypeptide which is an H chain containing an H chain variable region amino acid sequence of SEQ ID NO: 9; and a third and fourth polypeptide which are a commonly shared L chain containing an L chain variable region amino acid sequence of SEQ ID NO: 14; or

(c) a bispecific antibody comprising a first polypeptide which is an H chain containing the amino acid sequence of SEQ ID NO: 5; a second polypeptide which is an H chain containing the amino acid sequence of SEQ ID NO: 10; and a third and fourth polypeptide which are a commonly shared L chain containing the amino acid sequence of SEQ ID NO: 15.

[Claim 2]
The use of claim 1, wherein the maintenance dose is selected from following a) to c):
a) the maintenance dose which is to be administered in one single dose at 6 mg/kg of the antibody every four weeks,
b) the maintenance dose which is to be administered in two single doses of the antibody each at 3 mg/kg every four weeks, wherein one single dose of the maintenance dose at 3 mg/kg of the antibody is to be administered once every two weeks, and
c) the maintenance dose which is to be administered in four single doses each at 1.5 mg/kg of the antibody every four weeks, wherein one single dose of the maintenance dose at 1.5mg/kg of the antibody is to be administered once every week.

[Claim 3]
The use of claim 1 or 2, wherein the bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X is emicizumab.